Although we propose a rational therapeutic strategy to render niraparib more effective in killing tumor cells that can be further tested in the clinic, whether GCH1 could be a biomarker for sensitivity to PARP inhibitor treatment still warrants further investigations. Here, GCH1 is linked to neoplasm.